The Chemokine CX3CL1 Improves Trastuzumab Efficacy in HER2 Low-Expressing Cancer <i>In Vitro</i> and <i>In Vivo</i>.-论文-万方医学网

第一作者： Tobias F,Dreyer

第一单位： Department of Gynecology and Obstetrics, Technical University of Munich, Munich, Germany.

作者： Tobias F,Dreyer ^[1] ; Sabine,Kuhn ^[2] ; Christoph,Stange ^[1] ; Nadine,Heithorst ^[1] ; Daniela,Schilling ^[3] ; Jil,Jelsma ^[1] ; Wolfgang,Sievert ^[4] ; Stefanie,Seitz ^[1] ; Stefan,Stangl ^[4] ; Alexander,Hapfelmeier ^[5] ; Aurelia,Noske ^[6] ; Anja K,Wege ^[7] ; Wilko,Weichert ^[8] ; Jürgen,Ruland ^[9] ; Manfred,Schmitt ^[1] ; Julia,Dorn ^[1] ; Marion,Kiechle ^[1] ; Ute,Reuning ^[1] ; Viktor,Magdolen ^[1] ; Gabriele,Multhoff ^[4] ; Holger,Bronger ^[10]

作者单位： Department of Gynecology and Obstetrics, Technical University of Munich, Munich, Germany. ^[1] Department of Clinical Chemistry and Pathobiochemistry, Technical University of Munich, Munich, Germany. ^[2] Department of Radiation Oncology, Technical University of Munich, Munich, Germany.;Institute of Radiation Medicine (IRM), Department of Radiation Sciences (DRS), Helmholtz Zentrum Munich, Neuherberg, Germany. ^[3] Department of Radiation Oncology, Technical University of Munich, Munich, Germany. ^[4] Institute of Medical Informatics, Statistics and Epidemiology, School of Medicine, Technical University of Munich, Munich, Germany. ^[5] Department of Pathology, Technical University of Munich, Munich, Germany. ^[6] Department of Gynecology and Obstetrics, University Cancer Center Regensburg, Regensburg, Germany. ^[7] Department of Pathology, Technical University of Munich, Munich, Germany.;German Cancer Consortium (DKTK), partner site Munich, and German Cancer Research Center (DKFZ), Heidelberg, Germany. ^[8] Department of Clinical Chemistry and Pathobiochemistry, Technical University of Munich, Munich, Germany.;German Cancer Consortium (DKTK), partner site Munich, and German Cancer Research Center (DKFZ), Heidelberg, Germany. ^[9] Department of Gynecology and Obstetrics, Technical University of Munich, Munich, Germany. holger.bronger@tum.de.;German Cancer Consortium (DKTK), partner site Munich, and German Cancer Research Center (DKFZ), Heidelberg, Germany. ^[10]

主题词成年人(Adult);老年人(Aged);老年人, 80以上(Aged, 80 and over);动物(Animals);乳腺肿瘤(Breast Neoplasms);趋化因子CX3CL1(Chemokine CX3CL1);队列研究(Cohort Studies);抗药性, 肿瘤(Drug Resistance, Neoplasm);女(雌)性(Female);基因表达谱(Gene Expression Profiling);基因表达调控, 肿瘤(Gene Expression Regulation, Neoplastic);人类(Humans);Kaplan-Meiers评估(Kaplan-Meier Estimate);杀伤细胞, 天然(Killer Cells, Natural);肺肿瘤(Lung Neoplasms);小鼠(Mice);中年人(Middle Aged);预后(Prognosis);信号传导(Signal Transduction);肿瘤微环境(Tumor Microenvironment);青年人(Young Adult)

DOI 10.1158/2326-6066.CIR-20-0327

PMID 33906866

发布时间 2022-02-21

检索历史清除

The Chemokine CX3CL1 Improves Trastuzumab Efficacy in HER2 Low-Expressing Cancer <i>In Vitro</i> and <i>In Vivo</i>.

Cancer immunology research

相似文献

Cancer immunology research

相关期刊

参考文献：
指定格式：	NoteExpress EndNote RefWorks NoteFirst

检索历史 清除

The Chemokine CX3CL1 Improves Trastuzumab Efficacy in HER2 Low-Expressing Cancer <i>In Vitro</i> and <i>In Vivo</i>.

Cancer immunology research

相似文献

Cancer immunology research

相关期刊

检索历史清除